RNA-Seq: Less Lumping, More Splitting
Single-Cell RNA-Seq Detects Subtle Differences between Cellular Subtypes, Demands Specialized Methods of Data Analysis
Literature Review: Virus Neatly Organizing Its Own Nucleus
Phage Infection and Replication in a Bacterial Host
Researchers Seek Ways to Minimize Off-Target Effects
Literature Review: Dials for Cas9
Methods to Control Cas9-Based Technologies Across Numerous Dimensions Is Still Lacking
Prokarium is a biotechnology company with a vision to create the best platform for oral delivery of almost any recombinant protein vaccine. Its Vaxonella™ platform incorporates genetic and formulation technologies that are designed to optimize live bacterial vector-mediated antigen delivery: Spi-VEC, X-mark, ORT-VAC and BAR. Prokarium is based in Keele and London, UK.